You are here

Home » Content

KANSER HASTALARINDA KULLANILAN KEMOTERAPOTİK İLAÇLARIN ORAL MUKOZA VE LABİYAL MİNÖR TÜKRÜK BEZLERİ (LMT) ÜZERİNE OLAN UZUN SÜRELİ ETKİLERİNİN ARAŞTIRILMASI

LONG TERM ASSESSMENT OF CANCER CHE-MOTHERAPEUTICS ON ORAL MUCOSA AND MINOR LABIA SALIVARY GLANDS

Journal Name:

  • İstanbul Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 1993

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Chemotherapy has been indicated for the cure of various tumors or prior to radiotherapy and surgery. These therapeutics may lead to directly or indirectly changes on oral mucosa and minor salivary glands at a rate of% 40¬80. This study is carried out on chemotherapeutic drugs such as Cysplatin and 5-Florourasil which has not been investigated in regards with their effects on oral mucosa and labial minor salivary glands on patients who received cancer chemotherapaitics for a period of 3 mounths. In the tissue samples of these patients various rates of parakeratosis, fibrosis and atrophy has been observed. In their oral mucosa whereas, labial minor salivary glands samples showed mononuclear infiltration, atrophy, decreased secretion and interticiel fibrosis. It is concluded that despite three mounths after the termination of chemotherapy, oral mucosa and labial minor salivary gland samples of these patients have still been displayed the effects of medication.
Bookmark/Search this post with
Abstract (Original Language): 
Kemoterapotik ilaçlar çeşitli tümörlerde tedavi edici amaçla veya hastayı radyoterapiye ya da cerrahi girişime hazırlamak amacı ile kullanılırlar. Bu ilaçların kullanımı ile oral mukoza ve labial minör tükrük bezlerinde (LMT) direk veya indirek etki ile % 40-80 oranında değişikliklere neden olabilirler. Bu araştırma daha Önce oral mukoza ve labial minör tükrük bezi (LMT) üzerine uzun süreli etkileri hiç araştırılmamış olan Cisplatin ve 5-Florourasil gibi ke-moterapotiklerin etkilerini saptamak için, çeşitli kanser tiplerinden dolayı ortalama 3 ay önce tedavi edilmiş 13 kanser hastası üzerinde yapıldı. Hastalardan sağlanan doku örneklerinde oral mukozada çeşitli oranlarda parakeratoz, akantoz, displazi, atipî, mononükleer infıltrasyonu, fibro-zis ve atrofi gözlenirken LMT'de de mononükleer İnfiltras-yon, atrofi, sekresyon da azalma, intersitisiel fibrozis saptandı. Çalışmanın sonucunda, kemoterapotik ilaçlarla tedavi edilen kanser hastalarının oral mukoza ve LMT bezlerinde tedaviden 3 ay geçmiş olmasına rağmen, halâ bu ilaçların etkilerinin sürdüğü tespit edilmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-kanser-hastalarinda-kullanilan-kemoterapotik-ilaclarin-oral-mukoza-labiyal-minor-tukruk-bezleri-lmt-uzerine-olan-uzun-sureli-etkilerinin-arastirilmasi.pdf
  • 2
99
105
  • Turkish

REFERENCES

References: 

1. Bottomley, W.K., Perlin, E., Ross, G.R.: Antineoplastic agents and their oral manifestations. Oral. Surg. Oral. Med. Oral Pathol. 1977; 44: 527-34.
2. Dreizen, S.: Stomatotoxic manifestations of cancer che-motherarpy.J. Prost. Dent. 1978; 40: 650-655.
3. Dreizen, S.: Description and incidence of oral complications. NCIMonogr. 1990; 9: 11-15.
4. Dreizen, S., Bodey, G.P., Valdİviso, M.: Chemotherapy associated oral infections in adults with solid tumors. Oral. Surg. OralMed. OralPathol. 1983;55:113-120.
5. Dreizen, S., McCredİe, K.B., Bodey, G.P., et al.: Quantitative analysis of the oral complications of antileukemia chemothe-
rapy. OralSurg. OralMed. OralPathol. 1986; 62: 650-653.
6. Dreizen, S., McCredie, K.B., Bodey, G.P., Keating, M.J.: Mucocutaneous herpetic infections during cancer chemotherapy. Postgraduate Med. 1988; 84: 181-190.
7. Duperon, D.: The effect of topical leukovorin of the gingiva of long evens rats undergoing methotrexate therapy. J. Oral. Med. 1978; 33: 12-6.
8. Guggenheimer, J., Verbin, R.S., Appel, B.N., Schmutz, J.: Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa. OralSurg. OralMed. OralPathol. 1977; 44: 58-63.
9. Izutsu, K.T., Truelove, EX., Bleyer, W.A. et al: Whole sa-
Kanser Hastalarında Kullanılan Kemoterapotik İlaçların Oral mukoza ve Labİyal Minör Tükrük Bezleri (LMT) Üzerine 105 Olan Uzun Süreli Etkilerinin Araştırılması
liva
albumi
n as an indicator of stomatitis in cancer therapy patients. Cancer 1981; 48:1450-1454.
10. Lockhart, P.B., Sonİs, S.T.; Alterations in the oral mucosa caused by chemotherapeutic agents./. Dermatol. Surg. 1981; 7:1019-25.
11. Lockhart, P.B., Clark, J.R.: Oral complications following neoadjuvant chemotherapy in patients with head and neck cancer. NCTMonogr. 1990; 9: 99-101.
12. Main, B.E., Caiman, K.C., Ferguson, M.M. et al: The effect of cytotoxic therapy on saliva and oral flora. OralSurg. Oral Med. OralPathol. 1984; 58: 545-48.
13. Matejka, M., Nell, A., Kement, G., et al: Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br. J. Oral Maxillofac Sur. 1990: 28: 89-91.
14. Montgomery, M.T., Redding, S.W., LeMaistre, C.F.: The incidence of oral herpes simplex virus infection in patients undergoing cancer chemothreapy. Oral Sur. OralMed. Oral Pathol. 1986; 61: 238-42.
15. Pterson, D.E.: Pretrcament strategies for infection prevention in chemotherapy patients. NCIMonogr. 1990; 9: 61-71.
16. Rosenberg, S.W.: Oral complications of cancer chemotherapy - a review of 398 patients./. OralMed. 1986;41: 93-97.
17. Schubert, M.M., Izutsu, K.T.: Iatrogenic causes of salivary gland dysfunction. /. Dent. Res. 1987; 66: 680-88.
18. Schum, C.A., Izutsu, K.T., Molbo, D.M., et al: Changes in salivary buffer capacity in patients undergoing cancer chemotherapy./. OralMed. 1979; 34: 76-80.
19. Shklar, G.: The effect of 4-amino-N 10-methyipteroyl-glutamic acid on oral mucosa of experimental animals. J. Oral Ther. 1968; 4: 374-7 (Kaynak 19'dan alınmıştır).
20. Som's, S.T., Tracey, G, Shklar, G., Jenson, i., Florine, D.: An animal model for mucositis induced by cancer chemotherapy. Oral Surg. Oral Med. Oral Pathol. 1990; 69: 437-43.
21. Sonİs, S.t., Sonis, A.L., Lieberman, A.: Oral complications in patients receivihg treatment for malignan cies other than of the head and neck. J ADA 1978, 9: 169-72.
22. Squier, C.A.: Mucosal alterations. NCIMonogr. 1990; 9: 169-72.
23. Wolff, A., Atkinson, J.C., Macynski, A.A., Fox, P.C.: Pretherapy interventions to modify salivary dysfunction. NCI Monogr. 1990;9:87-90.

Thank you for copying data from http://www.arastirmax.com